C07K 2317/20
Characterized by taxonomic origin
Official title: characterized by taxonomic origin
C07K2317/20 (Characterized by taxonomic origin) appears on 16,226 US grants and 30,753 published applications in this corpus.
Search patents in C07K- Granted patents
- 16,226
- Published applications
- 30,753
- Assignees
- 5,607
- Inventors
- 35,475
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 3 | 0 |
| 1992 | 5 | 0 |
| 1993 | 10 | 0 |
| 1994 | 4 | 0 |
| 1995 | 9 | 0 |
| 1996 | 30 | 0 |
| 1997 | 63 | 0 |
| 1998 | 102 | 0 |
| 1999 | 121 | 0 |
| 2000 | 85 | 0 |
| 2001 | 79 | 30 |
| 2002 | 90 | 234 |
| 2003 | 83 | 895 |
| 2004 | 90 | 404 |
| 2005 | 79 | 464 |
| 2006 | 168 | 488 |
| 2007 | 249 | 480 |
| 2008 | 278 | 535 |
| 2009 | 304 | 758 |
| 2010 | 378 | 760 |
| 2011 | 423 | 894 |
| 2012 | 511 | 936 |
| 2013 | 597 | 1003 |
| 2014 | 668 | 1189 |
| 2015 | 771 | 1313 |
| 2016 | 869 | 1640 |
| 2017 | 933 | 1735 |
| 2018 | 986 | 1637 |
| 2019 | 1020 | 1796 |
| 2020 | 1117 | 1852 |
| 2021 | 1129 | 2074 |
| 2022 | 1044 | 2034 |
| 2023 | 933 | 2036 |
| 2024 | 1108 | 2230 |
| 2025 | 1126 | 1903 |
| 2026 | 754 | 1433 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- Aggrecan binding immunoglobulins6 Oct 2026US 12,753,224 B2Ablynx N. V.
- Anti-MS4A4A antibodies and methods of use thereof6 Oct 2026US 12,753,225 B2Alector LLC
- Methods for treating or preventing asthma by administering an il-4r antagonist8 Oct 2026US 2026/0306627 A1Regeneron Pharmaceuticals, Inc.
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Recombinant immunoglobin preparations4,785US 4,816,567 AGenentech, Inc. · 1989
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Recombinant altered antibodies and methods of making altered antibodies1,968US 5,225,539 AMedical Research Council · 1993